TY - JOUR
T1 - Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies
T2 - Recommendations by ClinGen's Inherited Cardiomyopathy Expert Panel
AU - ClinGen Cardiovascular Clinical Domain Working Group
AU - Kelly, Melissa A.
AU - Caleshu, Colleen
AU - Morales, Ana
AU - Buchan, Jillian
AU - Wolf, Zena
AU - Harrison, Steven M.
AU - Cook, Stuart
AU - Dillon, Mitchell W.
AU - Garcia, John
AU - Haverfield, Eden
AU - Jongbloed, Jan D.H.
AU - Macaya, Daniela
AU - Manrai, Arjun
AU - Orland, Kate
AU - Richard, Gabriele
AU - Spoonamore, Katherine
AU - Thomas, Matthew
AU - Thomson, Kate
AU - Vincent, Lisa M.
AU - Walsh, Roddy
AU - Watkins, Hugh
AU - Whiffin, Nicola
AU - Ingles, Jodie
AU - Van Tintelen, J. Peter
AU - Semsarian, Christopher
AU - Ware, James S.
AU - Hershberger, Ray
AU - Funke, Birgit
AU - Berg, Jonathan
AU - Milko, Laura
AU - Rivera Munoz, Edgar A.
AU - Ackerman, Michael
AU - Care, Melanie
AU - DeBacker, Julie
AU - Deitz, Hal
AU - Gollob, Michael
AU - Knowles, Joshua
AU - Loeys, Bart
AU - McKenna, Bill
AU - Milewicz, Dianna
AU - Novelli, Valeria
AU - Sturm, Amy
AU - Wilde, Arthur
N1 - Funding Information:
Research reported in this publication was supported by the National Human Genome Research Institute and funding from the National Institute of Child Health and Human Development and National Cancer Institute (awards U41HG006834 (H.R.) and U01HG007437 (J.B.)). J.I. was supported by a National Heart Foundation of Australia Future Leader Fellowship (100833). C.S. was supported by a National Health and Medical Research Council Practitioner Fellowship (1059156). J.W. was supported by the Wellcome Trust (107469/Z/15/Z), British Heart Foundation, Medical Research Council (UK), and the National Institute for Health Research Royal Brompton Biomedical Research Unit. The CMP-EP thanks Lisa Kurtz for her help revising and submitting the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2018 American College of Medical Genetics and Genomics.
PY - 2018/3/1
Y1 - 2018/3/1
N2 - Purpose: Integrating genomic sequencing in clinical care requires standardization of variant interpretation practices. The Clinical Genome Resource has established expert panels to adapt the American College of Medical Genetics and Genomics/Association for Molecular Pathology classification framework for specific genes and diseases. The Cardiomyopathy Expert Panel selected MYH7, a key contributor to inherited cardiomyopathies, as a pilot gene to develop a broadly applicable approach. Methods: Expert revisions were tested with 60 variants using a structured double review by pairs of clinical and diagnostic laboratory experts. Final consensus rules were established via iterative discussions. Results: Adjustments represented disease-/gene-informed specifications (12) or strength adjustments of existing rules (5). Nine rules were deemed not applicable. Key specifications included quantitative frameworks for minor allele frequency thresholds, the use of segregation data, and a semiquantitative approach to counting multiple independent variant occurrences where fully controlled case-control studies are lacking. Initial inter-expert classification concordance was 93%. Internal data from participating diagnostic laboratories changed the classification of 20% of the variants (n = 12), highlighting the critical importance of data sharing. Conclusion: These adapted rules provide increased specificity for use in MYH7-associated disorders in combination with expert review and clinical judgment and serve as a stepping stone for genes and disorders with similar genetic and clinical characteristics.
AB - Purpose: Integrating genomic sequencing in clinical care requires standardization of variant interpretation practices. The Clinical Genome Resource has established expert panels to adapt the American College of Medical Genetics and Genomics/Association for Molecular Pathology classification framework for specific genes and diseases. The Cardiomyopathy Expert Panel selected MYH7, a key contributor to inherited cardiomyopathies, as a pilot gene to develop a broadly applicable approach. Methods: Expert revisions were tested with 60 variants using a structured double review by pairs of clinical and diagnostic laboratory experts. Final consensus rules were established via iterative discussions. Results: Adjustments represented disease-/gene-informed specifications (12) or strength adjustments of existing rules (5). Nine rules were deemed not applicable. Key specifications included quantitative frameworks for minor allele frequency thresholds, the use of segregation data, and a semiquantitative approach to counting multiple independent variant occurrences where fully controlled case-control studies are lacking. Initial inter-expert classification concordance was 93%. Internal data from participating diagnostic laboratories changed the classification of 20% of the variants (n = 12), highlighting the critical importance of data sharing. Conclusion: These adapted rules provide increased specificity for use in MYH7-associated disorders in combination with expert review and clinical judgment and serve as a stepping stone for genes and disorders with similar genetic and clinical characteristics.
KW - Cardiomyopathy
KW - ClinGen
KW - HCM
KW - Myosin heavy chain 7
KW - Variant interpretation
UR - http://www.scopus.com/inward/record.url?scp=85044572143&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044572143&partnerID=8YFLogxK
U2 - 10.1038/gim.2017.218
DO - 10.1038/gim.2017.218
M3 - Article
C2 - 29300372
AN - SCOPUS:85044572143
SN - 1098-3600
VL - 20
SP - 351
EP - 359
JO - Genetics in Medicine
JF - Genetics in Medicine
IS - 3
ER -